Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient’s cancer, which may influence choice of treatment based on cancer stage and type SAN DIEGO, May 18, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) a global leader in…

Click here to view original post